Import Licenses, Customs, and What Is Not in the Dossier

Part of Regulatory Affairs and the Jurisdiction Map: Submissions and the Critical Path.

About 4 minutes. Free, in your language, no account needed.

Why this matters

A trial can be fully authorized in a country and unable to start, because the investigational product cannot lawfully enter it.

This surprises people because the import route is not part of the dossier, is frequently administered by a different body from the one that authorized the trial, and appears nowhere in the approval the team is celebrating. It is a separate permission with a separate process and a separate timeline, and it is routinely the last thing anyone checks.

What is actually required to get product into a country

An import license or permit, often specific to the product, the quantity and the consignee, and frequently requiring the trial authorization as a prerequisite. That prerequisite is what puts it after the authorization on the critical path rather than beside it.

Customs classification and documentation. Investigational product is not commercial goods and is frequently misclassified, which is a common cause of consignments held at a border. The documentation travels with the shipment and has to be right before it leaves.

A named importer or consignee with the legal standing to receive it. In several countries this must be an entity established locally, which is a corporate question with a lead time measured in weeks or months.

Release by a qualified person, where the framework requires it, before product may be used.

Controlled substance licensing, where applicable, which is its own regime with its own authority and is materially slower than ordinary import licensing.

A return or destruction route established before shipment, because several jurisdictions do not permit unused investigational product to simply leave or be destroyed without authorization.

The comparator and placebo problem

Teams plan the import of the investigational product and forget that a comparator and a placebo are also products crossing the same border, subject to the same requirements, and sometimes to different ones.

A comparator sourced commercially in one country and shipped to another is an export from the first as well as an import to the second. A comparator that is a controlled substance carries the controlled substance regime with it. A placebo, despite containing nothing active, is still a manufactured product requiring documentation of what it is and how it was made.

The characteristic failure is a study fully supplied with investigational product and unable to dose, because the comparator is at a border.

In practice

A country's trial authorization arrives in week nine, ahead of plan. The study team schedules site activation for week eleven.

The regulatory lead stops it, and the reason is the import chain. The import license application requires the trial authorization as an attachment, so it could not be submitted before week nine. Its own review period is four weeks. The local consignee entity is in place, which was established in month two precisely because it takes that long.

Shipment therefore cannot leave before week thirteen, arrives in week fifteen, and clears customs in week sixteen on a good run. Site activation in week eleven would mean an activated site with nothing to give anybody.

The lead's contribution was not discovering this in week nine. It was establishing the consignee in month two, which is the part that would have added twelve weeks if it had been discovered here.

What this looks like when it goes wrong

A shipment of investigational product arrives at a border with documentation that describes it using the sponsor's internal product code rather than a customs-recognized description.

Customs cannot classify it. The consignment goes into a holding facility whose temperature is monitored but not controlled to the product's requirements.

Eleven days later the documentation is corrected and the shipment is released, with a temperature excursion spanning the entire period. The product is quarantined on arrival pending a disposition decision, and the sites waiting for it wait another three weeks.

Nothing about the trial authorization was wrong. Nothing about the product was wrong. A description field on a customs document was wrong, and that was sufficient to cost a month and a shipment.

Key takeaways